FDA fast-tracks drug for spinal cord injury

Alan Condon -   Print  |

AbbVie's elezanumab on Sept. 29 received Fast Track designation for the treatment of patients with spinal cord injury.

Elezanumab, a monoclonal antibody, was designed by the biopharmaceutical company to block a molecule that can hinder neuronal regeneration and functional recovery after central nervous system damage.

AbbVie is developing elezanumab for spinal cord injuries, multiple sclerosis and acute ischemic stroke.

The FDA has also granted elezanumab orphan status, which decreases development costs and could increase profits if approved.

More articles on spine:
Dr. Mark Erickson performs 100th robotic-assisted pediatric spine surgery
6 spine surgeons on the biggest obstacle they face going forward
North American Spine Society recognizes 20 spine specialists under 40

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers